30th Transcatheter Cardiovascular Therapeutics Scientific Symposium (TCT 2018)

The efficacy of oral anticoagulation (OAC) alone without antiplatelet therapy in patients with atrial fibrillation (AF) and coronary artery disease (CAD) who have undergone percutaneous coronary intervention (PCI) remains to be seen, with findings of the OAC-ALONE* trial proving inconclusive, according to a study presented at the recent TCT 2018 symposium.

Percutaneous coronary intervention (PCI) with a thin composite wire strut, durable polymer-coated stent demonstrated comparable results to that using an ultrathin cobalt-chromium strut, bioresorbable polymer-coated stent, according to results of the BIONYX* trial presented at the recent TCT symposium (TCT 2018).

The risk of hospitalization due to heart failure was almost halved in patients with secondary mitral regurgitation who underwent transcatheter mitral valve repair plus medical therapy compared with those who underwent medical therapy alone, according to findings of the COAPT* trial.